Skip to search formSkip to main contentSkip to account menu

MEK-1/MEKK-1 Inhibitor E6201

Known as: E6201 
A synthetic, fungal metabolite analogue inhibitor of mitogen-activated protein kinase kinase 1 (MEK-1) and mitogen-activated protein kinase kinase… 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2019
2019
Correction to: Anti-tumor and anti-metastasis efficacy of E6201, a MEK1 inhibitor, in preclinical models of triple-negative breast cancer
Unfortunately in the original publication of the article, the author’s funding support has been mentioned incorrectly. The… 
2018
2018
Abstract 5780: E6201, a novel MEK1 inhibitor, suppresses the metastatic capability of triple-negative breast cancer cells
Background: Triple-negative breast cancer (TNBC) lacks the receptor targets ER, PR, and HER2 and thus it does not respond to… 
2016
2016
Bischerour , Julien and Chalmers , Ronald ( 2009 ) Base flipping in Tn 10 transposition : an active flip and capture mechanism
The bacterial Tn5 and Tn10 transposases have a single active site that cuts both strands of DNA at their respective transposon… 
2014
2014
Abstract 1698: Identification of drugs with eribulin combinatorial activity that kill both eribulin-sensitive and eribulin-insensitive tumor cells
Proceedings: AACR Annual Meeting 2014; April 5-9, 2014; San Diego, CA Eribulin mesylate, a nontaxane microtubule dynamics… 
2010
2010
E6201, a Novel Kinase Inhibitor of Mitogen-Activated Protein Kinase/Extracellular Signal-Regulated Kinase Kinase-1 and Mitogen-Activated Protein Kinase/Extracellular Signal-Regulated Kinase Kinase…
E6201 [(3S,4R,5Z,8S,9S,11E)-14-(ethylamino)-8,9,16-trihydroxy-3,4-dimethyl-3,4,9,10-tetrahydro-1H-2-benzoxacyclotetradecine-1,7… 
2010
2010
Phase I dose-escalation study of E6201, a MEK-1 inhibitor, in advanced solid tumors.
2505 Background: E6201 is a potent inhibitor of mitogen-activated protein kinase/extracellular signal-regulated kinase (MEK)-1… 
2009
2009
Abstract #3687: In vivo anticancer activity of E6201, a novel MEK1 inhibitor, against BRAF-mutated human cancer xenografts
AACR Annual Meeting-- Apr 18-22, 2009; Denver, CO The RAS/RAF/MEK/ERK signaling pathway has long been viewed as a crucial… 
Review
2009
Review
2009
Abstract #DDT02-1: Discovery and characterization of E6201: A potent natural product-inspired synthetic MEK1 inhibitor
AACR Annual Meeting-- Apr 18-22, 2009; Denver, CO Background The RAS/RAF/MEK/ERK signal transduction pathway regulates cell… 
2006
2006
Gemcitabine (G) plamsa and intracellular pharmacokinetics in E6201: Greater metabolite levels using fixed dosing rate (FDR) delivery.
2024 Background: Gemcitabine (G) is an antimetabolite which requires activation by the rate-limiting enzyme dCK to its active… 
2002
2002
Instructions to authors
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)